White House scraps key plan to lower U.S. drug prices, may target makers
The Trump administration on Thursday scrapped one of its most ambitious proposals for lowering prescription medicine prices, backing down from a policy aimed at health insurers and raising the possibility of new measures focused on drug makers. The abandoned proposal would have required health insurers ...
AstraZeneca bets $6.9 billion that Daiichi Sankyo therapy will transform cancer treatment
Britain’s AstraZeneca’s biggest deal in recent memory give it access to the Japanese drugmaker’s promising but difficult to pronounce cancer treatment: trastuzumab deruxtecan.
China's generic drug makers struggle to survive bulk-buy policy onslaught
Even after a plunge last month that wiped $46 billion off Chinese health-care stocks, domestic drug makers may be far from their floor as a Beijing-led policy shift gathers pace. China's plan to drive down generic drug prices through a centralized bulk procurement program is ...
Taisho said to near $1.6 billion deal for Bristol-Myers unit
Taisho Pharmaceutical Holdings Co. is nearing a deal to buy Bristol-Myers Squibb Co.'s French over-the-counter unit, people familiar with the matter said, as the Japanese drugmaker seeks to boost its overseas presence. An agreement for the consumer-health business could be announced as soon as this ...
Japan's Takeda to seek shareholder approval of Shire purchase plan Dec. 5
Takeda Pharmaceutical Co. said it will convene an extraordinary meeting of shareholders Dec. 5 to win approval for its plan to acquire Irish drugmaker Shire PLC that would make it a global top 10 company in the industry. But the Japanese pharmaceutical may face criticism ...
A trumpet melody used in the commercial for Taiko Pharmaceutical's Seirogan was registered as a trademark at the end of September, the first solely musical trademark to be registered in Japan.
Japan's push to curb drug costs seen risking trade row with U.S.
Japan's effort to rein in soaring health-care costs threatens to become a source of tension in economic relations with the U.S. after running into opposition from the American pharmaceutical industry. While the U.S. Commerce Department sees Japan's drug market, the world's third-largest, as the top ...
Daiichi Sankyo Inc. has settled thousands of lawsuits alleging its blood-pressure drugs caused intestinal damage, bringing to $339 million the amount the drugmaker has paid over the medicines. Daiichi officials agreed Monday to pay $300 million to resolve patient suits over its blood-pressure treatments Benicar, ...
Japan pushes for tighter control on drug pricing, crimping big pharma profits
President Donald Trump has pledged to reverse what he describes as "astronomical" drug prices in the United States. Thousands of kilometers away, Japan, long a profit sanctuary for multinational pharmaceutical companies, is taking a similar tack. Somewhere in the ballpark of ¥10 trillion is spent ...
Daiichi Sankyo awarded damages over cover-up at Indian ex-subsidiary
Daiichi Sankyo Co. said Friday that an international arbitration court has ordered former shareholders of an Indian firm it acquired in 2008 to pay the drugmaker around ¥56.2 billion ($524 million) for concealing critical information. Daiichi Sankyo sold its stake in Ranbaxy Laboratories Ltd. to ...
Japan takes aim at ballooning drug prices as costs strain health budget
When two of the world's biggest pharmaceutical companies announced a tie-up in Japan, its $78 billion drug industry took note. In November, the nation's largest drugmaker, Takeda Pharmaceutical Co., said it'd separate its off-patent products and share its extensive domestic distribution network with Israel's Teva ...
Japan bubble alert found in drug stock rally that won't quit
This year's Japanese stock rally has a surprise leader: pharmaceutical companies, which tend to lag behind the market when it gains. Drugmakers soared 22 percent, the most among the 33 industry groups on the benchmark Topix index, compared with a 10 percent gain for the ...
